A Small-Molecule Screen for Enhanced Homing of Systemically Infused Cells

被引:46
作者
Levy, Oren [1 ,2 ,3 ]
Mortensen, Luke J. [2 ,4 ,5 ]
Boquet, Gerald [6 ]
Tong, Zhixiang [1 ,2 ,3 ]
Perrault, Christelle [6 ]
Benhamou, Brigitte [6 ]
Zhang, Jidong [6 ]
Stratton, Tara [2 ,4 ,5 ]
Han, Edward [1 ,2 ,3 ]
Safaee, Helia [1 ,2 ,3 ]
Musabeyezu, Juliet [1 ,2 ,3 ]
Yang, Zijiang [1 ,2 ,3 ]
Multon, Marie-Christine [6 ]
Rothblatt, Jonathan [7 ]
Deleuze, Jean-Francois [6 ]
Lin, Charles P. [2 ,4 ,5 ]
Karp, Jeffrey M. [1 ,2 ,3 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Ctr Regenerat Therapeut, Div Biomed Engn,Dept Med,Med Sch, Cambridge, MA 02139 USA
[2] Harvard Stem Cell Inst, Cambridge, MA 02139 USA
[3] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA
[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA
[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA
[6] Sanofi R&D, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France
[7] Sanofi R&D, Cambridge, MA 02139 USA
来源
CELL REPORTS | 2015年 / 10卷 / 08期
基金
美国国家卫生研究院;
关键词
MESENCHYMAL STEM-CELLS; ENDOTHELIAL-CELLS; ADHESION; ACTIVATION; EXPRESSION; INHIBITOR; ICAM-1;
D O I
10.1016/j.celrep.2015.01.057
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Poor homing of systemically infused cells to disease sites may limit the success of exogenous cell-based therapy. In this study, we screened 9,000 signal-transduction modulators to identify hits that increase mesenchymal stromal cell (MSC) surface expression of homing ligands that bind to intercellular adhesion molecule 1 (ICAM-1), such as CD11a. Pretreatment of MSCs with Ro-31-8425, an identified hit from this screen, increased MSC firm adhesion to an ICAM-1-coated substrate in vitro and enabled targeted delivery of systemically administered MSCs to inflamed sites in vivo in a CD11a- (and other ICAM-1-binding domains)-dependent manner. This resulted in a heightened anti-inflammatory response. This represents a new strategy for engineering cell homing to enhance therapeutic efficacy and validates CD11a and ICAM-1 as potential targets. Altogether, this multi-step screening process may significantly improve clinical outcomes of cell-based therapies.
引用
收藏
页码:1261 / 1268
页数:8
相关论文
共 26 条
  • [1] Mesenchymal stem cell therapy: Two steps forward, one step back
    Ankrum, James
    Karp, Jeffrey M.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2010, 16 (05) : 203 - 209
  • [2] Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation
    Cutler, Corey
    Multani, Pratik
    Robbins, David
    Kim, Haesook T.
    Thuy Le
    Hoggatt, Jonathan
    Pelus, Louis M.
    Desponts, Caroline
    Chen, Yi-Bin
    Rezner, Betsy
    Armand, Philippe
    Koreth, John
    Glotzbecker, Brett
    Ho, Vincent T.
    Alyea, Edwin
    Isom, Marlisa
    Kao, Grace
    Armant, Myriam
    Silberstein, Leslie
    Hu, Peirong
    Soiffer, Robert J.
    Scadden, David T.
    Ritz, Jerome
    Goessling, Wolfram
    North, Trista E.
    Mendlein, John
    Ballen, Karen
    Zon, Leonard I.
    Antin, Joseph H.
    Shoemaker, Daniel D.
    [J]. BLOOD, 2013, 122 (17) : 3074 - 3081
  • [3] Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
    de Girolamo, Laura
    Lucarelli, Enrico
    Alessandri, Giulio
    Avanzini, Maria Antonietta
    Bernardo, Maria Ester
    Biagi, Ettore
    Brini, Anna Teresa
    D'Amico, Giovanna
    Fagioli, Franca
    Ferrero, Ivana
    Locatelli, Franco
    Maccario, Rita
    Marazzi, Mario
    Parolini, Ornella
    Pessina, Augusto
    Torre, Maria Luisa
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (13) : 2459 - 2473
  • [4] Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
    Dominici, M.
    Le Blanc, K.
    Mueller, I.
    Slaper-Cortenbach, I.
    Marini, F. C.
    Krause, D. S.
    Deans, R. J.
    Keating, A.
    Prockop, D. J.
    Horwitz, E. M.
    [J]. CYTOTHERAPY, 2006, 8 (04) : 315 - 317
  • [5] Enhanced mesenchymal cell engraftment by IGF-1 improves left ventricular function in rats undergoing myocardial infarction
    Enoki, Chiharu
    Otani, Hajime
    Sato, Daisuke
    Okada, Takayuki
    Hattori, Reiji
    Imamura, Hiroji
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 138 (01) : 9 - 18
  • [6] The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy
    Hoogduijn, Martin J.
    Popp, Felix
    Verbeek, Richard
    Masoodi, Mojgan
    Nicolaou, Anna
    Baan, Carla
    Dahlke, Marc-H
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2010, 10 (12) : 1496 - 1500
  • [7] Ruboxistaurin, a protein kinase C β inhibitor, as an emerging treatment for diabetes microvascular complications
    Joy, SV
    Scates, AC
    Bearelly, S
    Dar, M
    Taulien, CA
    Goebel, JA
    Cooney, MJ
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (10) : 1693 - 1699
  • [8] Mesenchymal Stem Cell Homing: The Devil Is in the Details
    Karp, Jeffrey M.
    Teol, Grace Sock Leng
    [J]. CELL STEM CELL, 2009, 4 (03) : 206 - 216
  • [9] Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB activation in endothelial cells
    Kim, I
    Moon, SO
    Kim, SH
    Kim, HJ
    Koh, YS
    Koh, GY
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) : 7614 - 7620
  • [10] Targeting Improves MSC Treatment of Inflammatory Bowel Disease
    Ko, In Kap
    Kim, Byung-Gyu
    Awadallah, Amad
    Mikulan, Jenifer
    Lin, Paul
    Letterio, John J.
    Dennis, James E.
    [J]. MOLECULAR THERAPY, 2010, 18 (07) : 1365 - 1372